Associations - EGFR exon 19 mutation

EGFR exon 19 mutation EGFR exon 19 mutation	Non Small Cell Lung Cancer NSCLC	EGFR exon 19 mutation EGFR exon 19 mutation	Non Small Cell Lung Cancer NSCLC	erlotinib Sensitive: A2 - Guideline	erlotinib Sensitive: A2 - Guideline
EGFR exon 19 mutation EGFR exon 19 mutation	Non Small Cell Lung Cancer NSCLC	EGFR exon 19 mutation EGFR exon 19 mutation	Non Small Cell Lung Cancer NSCLC	erlotinib + ramucirumab Sensitive: B - Late Trials	erlotinib + ramucirumab Sensitive: B - Late Trials
EGFR exon 19 mutation EGFR exon 19 mutation	Non Small Cell Lung Cancer NSCLC	EGFR exon 19 mutation EGFR exon 19 mutation	Non Small Cell Lung Cancer NSCLC	icotinib Sensitive: B - Late Trials	icotinib Sensitive: B - Late Trials
EGFR exon 19 mutation EGFR exon 19 mutation	Lung Adenocarcinoma LUAD	EGFR exon 19 mutation EGFR exon 19 mutation	Lung Adenocarcinoma LUAD	bevacizumab + erlotinib Sensitive: C3 – Early Trials	bevacizumab + erlotinib Sensitive: C3 – Early Trials
EGFR exon 19 mutation EGFR exon 19 mutation	Non Small Cell Lung Cancer NSCLC	EGFR exon 19 mutation EGFR exon 19 mutation	Non Small Cell Lung Cancer NSCLC	gefitinib Sensitive: C3 – Early Trials	gefitinib Sensitive: C3 – Early Trials
EGFR exon 19 mutation EGFR exon 19 mutation	Lung Adenocarcinoma LUAD	EGFR exon 19 mutation EGFR exon 19 mutation	Lung Adenocarcinoma LUAD	erlotinib Sensitive: C3 – Early Trials	erlotinib Sensitive: C3 – Early Trials
EGFR exon 19 mutation EGFR exon 19 mutation	Non Small Cell Lung Cancer NSCLC	EGFR exon 19 mutation EGFR exon 19 mutation	Non Small Cell Lung Cancer NSCLC	cisplatin + gefitinib + docetaxel Sensitive: C3 – Early Trials	cisplatin + gefitinib + docetaxel Sensitive: C3 – Early Trials
EGFR exon 19 mutation EGFR exon 19 mutation	Non Small Cell Lung Cancer NSCLC	EGFR exon 19 mutation EGFR exon 19 mutation	Non Small Cell Lung Cancer NSCLC	Immunotherapy Sensitive: C3 – Early Trials	Immunotherapy Sensitive: C3 – Early Trials
EGFR exon 19 mutation EGFR exon 19 mutation	Non Small Cell Lung Cancer NSCLC	EGFR exon 19 mutation EGFR exon 19 mutation	Non Small Cell Lung Cancer NSCLC	afatinib Sensitive: C3 – Early Trials	afatinib Sensitive: C3 – Early Trials
EGFR exon 19 mutation EGFR exon 19 mutation	Non Small Cell Lung Cancer NSCLC	EGFR exon 19 mutation EGFR exon 19 mutation	Non Small Cell Lung Cancer NSCLC	FCN-411 Sensitive: C3 – Early Trials	FCN-411 Sensitive: C3 – Early Trials
EGFR exon 19 mutation EGFR exon 19 mutation	Pancreatic Adenocarcinoma Pancreatic Adenocarcinoma	EGFR exon 19 mutation EGFR exon 19 mutation	Pancreatic Adenocarcinoma Pancreatic Adenocarcinoma	erlotinib Sensitive: C4 – Case Studies	erlotinib Sensitive: C4 – Case Studies
EGFR exon 19 mutation EGFR exon 19 mutation	Small Cell Lung Cancer Small Cell Lung Cancer	EGFR exon 19 mutation EGFR exon 19 mutation	Small Cell Lung Cancer Small Cell Lung Cancer	osimertinib Sensitive: C4 – Case Studies	osimertinib Sensitive: C4 – Case Studies
EGFR exon 19 mutation EGFR exon 19 mutation	Non Small Cell Lung Cancer NSCLC	EGFR exon 19 mutation EGFR exon 19 mutation	Non Small Cell Lung Cancer NSCLC	osimertinib Sensitive: C4 – Case Studies	osimertinib Sensitive: C4 – Case Studies